Acumen Pharmaceuticals (ABOS) Invested Capital (2020 - 2026)

Acumen Pharmaceuticals' Invested Capital history runs 7 years deep, the most recent figure standing at $104.4 million for Q1 2026.

• In Q1 2026, Invested Capital fell 43.58% year-over-year to $104.4 million; the TTM figure through Mar 2026 stood at $104.4 million (down 43.58% YoY), while the FY2025 annual figure was $92.8 million, down 56.06% from the prior year.
• Invested Capital came in at $104.4 million for Q1 2026 at Acumen Pharmaceuticals, up from $92.8 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $296.9 million in Q4 2023 to a low of $92.8 million in Q4 2025.
• A 5-year average of $200.4 million and a median of $196.7 million in 2022 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital jumped 575.32% in 2022 and tumbled 56.06% in 2025, its largest moves.
• Acumen Pharmaceuticals' Invested Capital stood at $188.8 million in 2022, then soared by 57.26% to $296.9 million in 2023, then retreated by 28.85% to $211.2 million in 2024, then sank by 56.06% to $92.8 million in 2025, then increased by 12.47% to $104.4 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $104.4 million, $92.8 million, and $120.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison